other material
confidence high
sentiment positive
materiality 0.50
Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies
Genprex, Inc.
- Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.
- Patent expands IP portfolio previously granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.
- Reqorsa is initially being developed for lung cancer; preclinical data shows complementarity with targeted drugs and immunotherapies.
- Israel lung cancer cases rose 33% in a decade; 200 new cases/month; leading cancer death cause in 2021.